PUBLICATION IN ACCORDANCE WITH ARTICLES 14 AND 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

Fri Mar 8, 2013 12:01pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130308:nHUGcYP3


REGULATED INFORMATION

GHENT, Belgium, 8 March 2013 - Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company
focused on the discovery and development of Nanobodies(R), announces today that the closing of its
private placement ("Accelerated Bookbuild Offering"/"ABO") took place on 5 March 2013 and as a
result, Ablynx issued 4,377,919 new shares. In addition, 348,400 new shares were issued that same
day as a result of the exercise of 641,800 warrants.

Ablynx NV also publishes the following information in accordance with article 15 of the Law of 2
May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading
on a regulated market (the "Transparency Law"):

 Total amount of the share capital:                  EUR90,653,858.30  
 Total number of securities carrying voting rights:  48,505,516        
 Total number of voting rights (denominator):        48,505,516        


Ablynx NV has in total 3,904,145 outstanding warrants, of which 1,657,700 warrants give the holder
the right to a total of 828,850 shares (two warrants giving the right to subscribe to one share)
and of which 2,246,445 warrants give the holder the right to a total of 2,246,445 shares (one
warrant giving the right to subscribe to one share). The acceptance and issuing of 467,500
warrants (one warrant giving the right to subscribe to one share) is pending. The total number of
voting rights, which can be acquired as a result of the exercise of the outstanding warrants,
amounts to 3,075,295.

In addition, Ablynx NV announces, in accordance with article 14 of the Law of 2 May 2007 on the
publication of major shareholdings in issuers whose shares are admitted to trading on a regulated
market (the "Transparency Law"), that it has received the following transparency notifications
between 28 February and 7 March 2013.

 Notifier(s)                                                                                                            Number of voting rights  Percentage of voting rights  
 Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV1         5,825,939                    12.01%            
 Sofinnova Partners SAS                                                                                                        4,675,587                    9.63%             


1 Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life Sciences 2004 NV.
Gimv NV (2,463,320 voting rights), Adviesbeheer Gimv Life Sciences NV (0 voting rights),
Adviesbeheer Gimv Life Sciences 2004 NV (433,745 voting rights) and Biotech Fonds Vlaanderen NV
(2,928,874 voting rights) are acting in mutual agreement. The Flemish Region in Belgium is the
ultimate shareholder of  Biotech Fonds Vlaanderen NV.

The full versions of the transparency notifications are available on the website of Ablynx
(www.ablynx.com http://www.ablynx.com/  - investor relations).

About Ablynx

Ablynx http://www.ablynx.com/  is a biopharmaceutical company engaged in the discovery and
development of NanobodiesĀ®
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/ , a
novel class of therapeutic proteins based on single-domain antibody fragments, for a range of
serious human diseases, including inflammation, haematology, oncology and pulmonary disease.
Today, the Company has approximately 25 programmes in the pipeline
http://www.ablynx.com/en/research-development/pipeline/  and five Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant partnerships with
major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck &
Co. The Company is headquartered in Ghent, Belgium. 

More information can be found on www.ablynx.com http://www.ablynx.com/ .

For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / 
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com mailto:edwin.moses@ablynx.com 

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03 
e:  marieke.vermeersch@ablynx.com  mailto:marieke.vermeersch@ablynx.com%20 
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx@mcomgroup.com mailto:ablynx@mcomgroup.com

press release in pdf http://hugin.info/137912/R/1684075/551329.pdf 


----------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE


HUG#1684075

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.